Company Overview

SmartCella was  founded in 2014, is based in Tullinge, Sweden and  has three units: 

• SmartWise with the FDA-approved Extroducer, an endovascular device that enables direct tissue or organ infusion to hard-to-reach organs and tumors. 
• SmartCella Solutions creating novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs. 
• Procella with advanced capabilities within stem cell therapy development and cGMP manufacturing inhouse. Procella collaborates with AstraZeneca on a globally licensed cardiac stem cell therapy to repair parts of the heart damaged from a heart attack and has a growing pipeline of stem cell therapies.